Basit öğe kaydını göster

dc.contributor.authorTuzcu, Bilge
dc.contributor.authorÜner, Burcu
dc.date.accessioned2025-02-28T19:15:29Z
dc.date.available2025-02-28T19:15:29Z
dc.date.issued2025en_US
dc.identifier.citationTuzcu B., Üner B. Targeted ‘Tfam’ Activation and ‘Mitoq’ Therapy for Pearson Syndrome. III. International Mineral Water Congress, 2025, 44-45.en_US
dc.identifier.isbn978-625-94264-6-4
dc.identifier.urihttps://kongre.madensuyu.org/en/
dc.identifier.urihttps://hdl.handle.net/20.500.12780/1027
dc.description.abstractThis study investigates a novel therapeutic strategy for Pearson syndrome by combining Mitochondrial Transcription Factor A (TFAM) activation with the antioxidant MitoQ in a dual-loaded nanoparticle system. Pearson syndrome, a mitochondrial disorder characterized by severe multi-systemic effects due to mitochondrial DNA deletions, necessitates targeted interventions aimed at restoring mitochondrial function and reducing oxidative damage. (1) In this study, we developed a dual therapeutic platform encapsulating siRNA targeting TFAM alongside MitoQ, aiming to simultaneously enhance mito- chondrial biogenesis and neutralize reactive oxygen species (ROS). The nanoparticles were successfully formulated with two distinct particle populations, concentrated at 97 nm and 132.7 nm, with an average particle size of 116.3 nm, ensuring optimal cellular uptake and mitochondrial target- ing. The surface charge, measured as +53.5 mV, indicated strong colloidal stability and facilitated intracellular delivery. Both the siRNA and MitoQ demonstrated high loading efficiencies, achieving 93.4% and 94.4% encapsu- lation, respectively, with an overall system encapsulation efficiency of 92.3%. The therapeutic efficacy of the system was further supported by functional studies. ROS levels were significantly reduced by 2.1-fold with MitoQ treat- ment alone, while the combined siRNA-MitoQ system achieved a 1.9-fold re- duction, highlighting the synergistic effect of antioxidant activity and TFAM modulation. Additionally, ATP production, a critical indicator of mitochondrial function, was elevated by 3.4-fold in cells treated with the dual-loaded nanoparticles, demonstrating the system’s potential to restore energy pro- duction in mitochondria-compromised cells. These results suggest that this dual-targeted nanoparticle system, leveraging the complementary actions of siRNA-induced TFAM activation and MitoQ’s antioxidant properties, presents a promising therapeutic approach for miti- gating mitochondrial dysfunction and oxidative stress in Pearson syndrome.en_US
dc.language.isoengen_US
dc.publisherKızılay Culture and Arten_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPearson syndrome therapyen_US
dc.subjectMitochondrial biogenesisen_US
dc.subjectNanoparticle based therapyen_US
dc.subjectOxidative stress reductionen_US
dc.titleTargeted ‘Tfam’ activation and ‘Mitoq’ therapy for pearson syndromeen_US
dc.typeconferenceObjecten_US
dc.contributor.departmentİstanbul Kent Üniversitesi, Fakülteler, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümüen_US
dc.contributor.authorID0009-0005-2601-0199en_US
dc.contributor.authorID0000-0003-4691-0432en_US
dc.contributor.institutionauthorTuzcu, Bilge
dc.contributor.institutionauthorÜner, Burcu
dc.identifier.startpage44en_US
dc.identifier.endpage45en_US
dc.relation.journalIII. International Mineral Water Congressen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster